LACTULOSE SOLUTION USP - LIQ 667MG/ML 667 MG — DIN 02148056
LACTULOSE : 667 MG · BDH INC. · LIQUID · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is LACTULOSE SOLUTION USP - LIQ 667MG/ML?
LACTULOSE SOLUTION USP - LIQ 667MG/ML 667 MG contains LACTULOSE : 667 MG. It is listed in the Health Canada Drug Product Database under DIN 02148056, held by BDH INC., supplied as LIQUID for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Aug-1999. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Lactulose cost around the world?
Lactulose is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 33 | USD███.██ |
| Saudi Arabia | public | 12 | 15 | SAR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 5 | 13 | BRL███.██ |
| Morocco | PPV (public price) | 5 | 9 | MAD███.██ |
| United Arab Emirates | public | 6 | 7 | AED███.██ |
| Bahrain | retail (max) | 5 | 5 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
85 pack listings across 40 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Lactulose pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Lactulose in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Lactulose, across 28 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 2 | RATIO-LACTULOSE, TEVA-LACTULOSE | Sourceable in Canada |
| PHARMASCIENCE INC | 3 | 1 | PHARMA-LACTULOSE, PMS-LACTULOSE SYR 667MG/ML, PMS-LACTULOSE-PHARMA | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP-LACTULOSE | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | LACTULOSE | Sourceable in Canada |
| HOECHST MARION ROUSSEL CANADA INC. | 2 | 0 | CEPHULAC SYR 667MG/ML, CHRONULAC SYR 667MG/ML | No marketed DIN |
| ORBUS PHARMA INC | 2 | 0 | JAMP-LACTULOSE, ORB-LACTULOSE | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 2 | 0 | RATIO-LACTULOSE | No marketed DIN |
| ROUGIER PHARMA DIVISION OF RATIOPHARM INC | 2 | 0 | COMALOSE R SIROP 10GM/15ML, LACTULAX SIROP 10GM/15ML | No marketed DIN |
| SOLVAY PHARMA INC | 2 | 0 | DUPHALAC, DUPHALAC DRY | No marketed DIN |
| PHARMACARE LTD., SOUTH AFRICA | 1 | 0 | WOODWARD'S LAXATIVE SYRUP | No marketed DIN |
| PRO DOC LIMITEE | 1 | 0 | PRO-LACTULOSE - 667 | No marketed DIN |
| STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | 1 | 0 | LACTULOSE SYRUP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 667 MG |
|---|---|
| Dosage form | LIQUID |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lactulose |
|---|---|
| ATC code | A06AD11 |
| AHFS class | 56:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02148056 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2148056 |
| Brand name | LACTULOSE SOLUTION USP - LIQ 667MG/ML |
| Generic / active ingredient | LACTULOSE : 667 MG |
| Market authorization holder | BDH INC. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AD11 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A06AD |
| Current status | CANCELLED POST MARKET |
| Status date | 11-Aug-1999 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 28 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-LACTULOSE | 667 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02295881 |
| LACTULOSE | 667 MG | SOLUTION | SANIS HEALTH INC | MARKETED | 02412268 |
| PMS-LACTULOSE-PHARMA | 667 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | 02469391 |
| RATIO-LACTULOSE | 667 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 00854409 |
| TEVA-LACTULOSE | 667 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02331551 |
| CEPHULAC SYR 667MG/ML | 667 MG | SYRUP | HOECHST MARION ROUSSEL CANADA INC. | CANCELLED POST MARKET | 02091925 |
| CHRONULAC SYR | 667 MG | SYRUP | MERRELL PHARMS INC., DIVISION OF MERRELL DOW (CAN) | CANCELLED POST MARKET | 00534528 |
| CHRONULAC SYR 667MG/ML | 667 MG | SYRUP | HOECHST MARION ROUSSEL CANADA INC. | CANCELLED POST MARKET | 02091917 |
| COMALOSE R SIROP 10GM/15ML | 10 G / 15 ML | SYRUP | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | 00651796 |
| DUPHALAC | 95 G / 100 G | POWDER | SOLVAY PHARMA INC | CANCELLED POST MARKET | 02231527 |
2 · Same class — other molecules in ATC A06AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Macrogol | CLARILAX · CLEARLAX · COLAXOR · COMFILAX · +17 more | 22 | 12 | Yes |
| Lactulose | CEPHULAC SYR 667MG/ML · CHRONULAC SYR · CHRONULAC SYR 667MG/ML · COMALOSE R SIROP 10GM/15ML · +20 more | 28 | 5 | Yes |
| Macrogol, Combinations | COLYTE · JAMP-ELECTROPEG · JAMP-ELECTROPEG WITH FLAVOUR PACKET · JAMPLYTE · +3 more | 8 | 3 | Yes |
| Mineral Salts In Combination | CEO-TWO BOWEL EVACUANT SUPPOSITORIES · EAU PURGATIVE RIGA · ELECTROPEG SOLUTION · GOLYTELY GI LAVAGE SOLUTION · +8 more | 13 | 1 | Yes |
| Magnesium Sulphate | EPSOM SALT PWS 100% · EPSOM SALTS · SEL D EPSOM | 6 | 0 | Not in Canada |
| Magnesium Sulphate, Combinations | AGOBYL GRANULE · AGOBYL LIQUIDE · FORMULE 1705 - LIQ | 3 | 0 | Not in Canada |
| Sodium Phosphate | EURO-PHOSPHATES SOLUTION · PHOSPHO-SODA BUFFERED SALINE LAXATIVE · PMS-PHOSPHATES SOLUTION | 3 | 0 | Not in Canada |
| Sorbitol | SORBITOL ROUGIER PWS 5GM | 1 | 0 | Not in Canada |
| Sodium Tartrate | LIMONADE RODECA | 1 | 0 | Not in Canada |
| Magnesium Oxide | MAGNESIUM CITRATE ORAL SOLUTION | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A06A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A06AB | Bisacodyl · Bisacodyl, Combinations · Cascara · Cascara, Combinations · Castor Oil · +9 more | 239 | 25 |
| A06AA | Docusate Sodium · Docusate Sodium, Combinations · Liquid Paraffin · Liquid Paraffin, Combinations | 144 | 22 |
| A06AX | Glycerol · Linaclotide · Lubiprostone · Other Laxatives · Plecanatide · +2 more | 30 | 14 |
| A06AH | Methylnaltrexone Bromide · Naloxegol | 5 | 3 |
| A06AG | Bisacodyl · Combinations · Docusate Sodium, Incl Combinations · Sodium Phosphate | 7 | 1 |
| A06AC | Ispaghula (Psylla Seeds) · Ispaghula, Combinations · Linseed · Methylcellulose · Polycarbophil Calcium · +2 more | 79 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LACTULOSE SOLUTION USP - LIQ 667MG/ML called?
The same molecule, Lactulose, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DUPHALAC | Latin | Bahrain, Brazil, Morocco |
| LACTULONA | Latin | Brazil |
| LAEVOLAC | Latin | Morocco |
| LACTOSAN | Latin | Brazil |
| LAQUIXAN | Latin | Brazil |
| LAXOLAC SYRUP | Latin | Saudi Arabia |
| PENTALAC | Latin | Brazil |
| RIALAC LIQUID | Latin | Saudi Arabia |
| Soflax® | Latin | United Arab Emirates |
| DUPHALAC ORAL SOLUTION | Latin | Saudi Arabia |
| Duphalac® | Latin | United Arab Emirates |
| EVA Q | Latin | Bahrain |
| EZILAX | Latin | Bahrain |
| LACTULAX | Latin | Morocco |
| Lactulose | Latin | United Arab Emirates |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.